Reply to correspondence on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK”

Article information

Clin Mol Hepatol. 2025;31(1):e123-e124
Publication date (electronic) : 2024 November 6
doi : https://doi.org/10.3350/cmh.2024.0966
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
Corresponding author : Yang-Hyun Baek Department of Internal Medicine, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-gu, Busan 49201, Korea Tel: +82-51-240-2728, Fax: +82-51-240-2087, E-mail: p100100@dau.ac.kr
Editor: Han Ah Lee, Chung-Ang University College of Medicine, Korea
Received 2024 October 30; Accepted 2024 November 1.
Keywords: COVID-19; PASC; Treatment

Dear Editor,

I am grateful for the additional insights provided by Professor Yon and Ha et al. in response to my editorial comment [1,2]. The authors reported that the incidence of gastrointestinal disease, hepatobiliary disease, and other digestive abnormalities increased in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the post-acute phase from three large-scale population-based cohorts [3]. The strength of this study is that it showed the risk of post-acute sequelae of COVID-19 (PASC) for the digestive organs across diverse disease entities, coronavirus disease 2019 (COVID-19) severity, changes over time and the presence or absence of vaccination.

In this study, the risk of gastrointestinal disease remained high after 6 months of COVID-19 infection, although the hazard ratio tended to decrease with time. A recent metaanalysis reported that the pooled prevalence estimates for PASC involving various organs were 45.06%, 41.30% and 41.32%, respectively, when the follow-up or assessment timepoint was categorized as ≥3rd, ≥6th, and ≥12th months after the index date [4]. Another recent study on the risk of PASC over a longer period has been published [5]. This study analyzed the risk of death and PASC over 3 years from a cohort of 135,161 people with SARS-CoV-2 infection and 5,207,835 controls from the US Department of Veterans Affairs. They showed that the risk of PASC decreased over the 3 years, but three organ systems still showed an increased risk in the third year, including neurologic, pulmonary and gastrointestinal disorders. The pathophysiology of PASC is not fully understood, but it was associated with several factors, including viral persistence, organ damage, inflammation, and immune dysregulation [6]. In addition, socioeconomic factors, pre-existing comorbidities, assess to health-care and the consequences of critical illness may influence the risk of PASC. These complex factors can act together to cause PASC over a short or longer period of time. The diagnosis of PASC is based on the history and clinical symptoms, excluding other diseases. Therefore, it is necessary to take a careful history, keeping in mind that there may be long-term effects of PASC for digestive system-related symptoms or signs.

So date, there is no standard treatment for PASC. There have been studies on the alleviation of gastrointestinal manifestations of PASC with vaccination and antiviral therapy [7-10]. As Professor Yon and Ha, et al commented, It would be premature to make a definitive statement regarding the protective effect of vaccination on gastrointestinal manifestations during post-COVID. However, several studies have shown the safety of COVID-19 vaccination and positive results in alleviating gastrointestinal manifestations during post-COVID [7-9]. Therefore, vaccination should not be hindered or discouraged. Another study presented a deep multi-omic, longitudinal investigation of 309 COVID-19 patients from initial diagnosis to convalescence (2–3 months later), integrated with clinical data and patient-reported symptoms [10]. The authors suggested that the importance of detectable virus at clinical diagnosis as a PASC factor may suggest antivirals administered early in the disease course may be beneficial not only for treating acute COVID-19, but also for reducing later PASC.

PASC is a complex and poorly understood condition, that can affect people for 2 weeks, months, or even years after their initial COVID-19 infection. Future research is needed to better understand the pathogenesis of PASC and multidisciplinary intervention may be required to provide a personalized treatment and rehabilitation.

Notes

Conflicts of Interest

The author has no conflicts to disclose.

Abbreviations

COVID-19

coronavirus disease 2019

PASC

post-acute sequelae of COVID-19

SARS-CoV-2

severe acute respiratory syndrome coronavirus 2

References

1. Lee K, Park J, Lee J, Lee H, Ha Y, Yon DK. Correspondence to editorial on “Long-term |gastrointestinal and hepatobiliary outcomes of COVID-19: a multinational population-based cohort study from South Korea, Japan, and the UK”. Clin Mol Hepatol 2025;31:e87–e89.
2. Baek YH. Understanding the impact on digestive disease in the post-COVID-19 condition: Editorial on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK”. Clin Mol Hepatol 2025;31:319–322.
3. Lee K, Park J, Lee J, Lee M, Kim HJ, Son Y, et al. Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: a multinational population-based cohort study from South Korea, Japan, and the UK. Clin Mol Hepatol 2024;30:943–958.
4. Sk Abd Razak R, Ismail A, Abdul Aziz AF, Suddin LS, Azzeri A, Sha’ari NI. Post-COVID syndrome prevalence: a systematic review and meta-analysis. BMC public Health 2024;24:1785.
5. Cai M, Xie Y, Topol EJ, Al-Aly Z. Three-year outcomes of postacute sequelae of COVID-19. Nat Med 2024;30:1564–1573.
6. Lam ICH, Wong CKH, Zhang R, Chui CSL, Lai FTT, Li X, et al. Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK. EClinicalMedicine 2023;60:102000.
7. Boston RH, Guan R, Kalmar L, Beier S, Horner EC, Beristain-Covarrubias N, et al. Stability of gut microbiome after COVID-19 vaccination in healthy and immuno-compromised individuals. Life Sci Alliance 2024;7:e202302529.
8. James D, Jena A, Bharath PN, Choudhury A, Singh AK, Sebastian S, et al. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis. Dig Liver Dis 2022;54:713–721.
9. Hong Y, Che T, Shen X, Chen J, Wang K, Zhao L, et al. The association of three vaccination doses with reduced gastrointestinal symptoms after severe acute respiratory syndrome coronavirus 2 infections in patients with inflammatory bowel disease. Front Med (Lausanne) 2024;11:1377926.
10. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022;185:881–895.e20.

Article information Continued